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Dr Ronald Fairman (Philadelphia, Pa). Does this type of
analysis assist you in terms of decision-making preoperatively? For
example, does it help you decide who might benefit from neuro-
genic thoracic outlet intervention?
Dr Rotellini-Coltvet. The scattergrams are not very wide at
the preoperative point, noting that the patients appear to be about
the same at baseline. However, what we did find postoperatively
and via a chart review was an ability to appropriately identify and
select patients preoperatively.
Preoperative components in selected appropriate neurogenic
patients include the following: knowing the patient for a long
period of time (around 2 years), confirm that the patient has
completed the physical therapy protocol, rule out C-spine disease
with a C-spine magnetic resonance imaging (MRI) scan, deter-
mine if pain management and/or pain medications are adequate in
controlling the pain, patient has a positive diagnostic lidocaine
block to confirm if surgical intervention will be successful, and
possesses motivation to return to work or their hobby.
A red flag for us is if they e-mail or call us more than three
times in 1 week. If this occurs, we bring the patient in for a
follow-up and implement a “tough love” stance.
Dr Freischlag. Really, we looked at whether or not the survey
could predict outcome, and because they all looked similar on
baseline, we haven’t been able to do that. We hope, as we follow
along, to be able to predict that, but for right now we haven’t been
able to use this survey as a prediction of success.
Dr Herbert Machleder (Los Angeles, Calif). Dr Freischlag
and her team, first at UCLA and then at Johns Hopkins, have made
major contributions to the literature and to our understanding of
TOS, and this is another beautifully presented paper.
I had one concern about the methodology. In the 38 ques-
tions on the DASH, developed as it was for primarily musculoskel-
etal problems, there is one question about dysesthesias, but there
are none about vascular symptoms; venous or arterial. This gives
rise to a problem called the “ceiling effect.” Where there are
insufficient questions in the domain of the disorder that you’re
examining, the patient really can’t reflect improvement on theIn the only other published paper that used the DASH to
assess surgical treatment of Paget-Schroetter Syndrome, the sur-
geons found that there was no difference in the DASH score
postoperatively, even though their surgical results were excellent.
They had achieved a normal hemodynamic status and there were
no episodes of re-thrombosis.
Could you refine the test so that it better addresses the
particular disability of the vascular TOS patient, before the test is
more widely disseminated and more widely used to evaluate TOS
treatment? As it is now presented in both papers, Paget-Schroetter
patients seem to have less initial disability and consequently less
improvement postoperatively. But, I think this may be an under-
estimation, there not being any questions about cyanosis, edema,
re-thrombosis, and venous “claudication”, etc.
Dr Rotellini-Coltvet. This was one of the concerns with
using the DASH as a solo instrument, that’s why the SF-12 was
added as a complementary measurement as it does look at overall
health status.
Dr Freischlag. I think we’re going to look at whether or not
we should use the DASH instrument. We did see improvement
with that and it did seem to match to the SF-12.
Dr Robert Thompson (St. Louis, Mo). One of the concerns I
had with the data you showed is that there was an overall retention
or response rate of 48% of all the patients that you initially enrolled
or operated on. Can you give us some insight into what the reasons
were that you only retained 48%, because this is otherwise a highly
devoted group of patients that you follow closely. Have you had a
chance to go back and look at entry criteria or data from the
patients that did not continue on and complete the entire survey
process? Were they in any way different than those who did
complete the survey? Could the data be skewed in any way by the
48% who did respond?
Dr Rotellini-Coltvet. It’s interesting because when we re-
viewed the charts, we found that the patients who were complain-
ing more were the ones completing the surveys. They were the
patients that we were seeing more of in the clinic. When patients
did well, we didn’t see or hear from them as much – they were too
busy enjoying life again. So for the most part, I think our data
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completed surveys from the patients who were doing well.
I think it would be helpful and beneficial if we could create a
web-based survey. We have many patients that live internationally
and travel across the country to see us that we lose patients purely
based on distance. Additionally, creating a shorter survey may also
increase response rates.
Dr Karl Illig (Rochester, NY). This is a very critical avenue
of exploration. As everybody who treats TOS knows, it’s a real
syndrome, but it’s very fuzzy. Most of the fuzziness arises from
the fact that we have no objective tests available for diagnosis.
While your data don’t strictly help us with diagnosis, I believe
that this sort of investigation is critical in that it starts to put us
on a little firmer quantitative platform. Rob Thompson, Julie
Freischlag, and a few others are forging ahead with a National
Institute of Health (NIH) proposal to help put some 21st
century science behind this diagnosis, so keep your eyes out for
efforts in this arena.
I am most interested in the scattergrams in the program book.
It looks like patients with neurogenic thoracic outlet seem to
continue to improve over the years, whereas those with venous
problems seem to improve more rapidly but then level off. Can you
give us any more insights from the shapes of your curves or from
your other observations?
You’re obviously accepting DASH and SF-12 as the best
instruments for this sort of evaluation we have at the present.
Do you have any plans to go further and perhaps create some-
thing a little more specific for thoracic outlet syndrome? In
other words, can you use your experience so far to work on an
outcomes evaluation instrument that is actually specific for this
disease entity?
Dr Rotellini-Coltvet. It’s been very rewarding working with
Dr Freischlag and over the course of the past 2 years I have seen our
practice change to better care for our patients. For example,
looking at the neurogenic TOS patients in particular, over time we
have been getting better at identifying recurrent symptoms faster
and implementing more aggressive therapy sooner. Therefore, it
would make sense why we are seeing improvement following lapses
at 24 months.
Dr Freischlag. Well, actually Dr Chang, who is sitting in the
front row also, works with us and helped us devise these instru-
ments. And that’s going to be one of his plans is to get a more
specific survey that we can then validate and then utilize as we go
forward. Even though these tools were good, and they did show
improvement, but it would be nice to be able to predict outcomes,
like you all want us to do. We do this survey, you look at it, you go,
okay, this one is going to do really well with the operation. And
that would be one contribution we can make.
We weren’t quite sure we were going to show anybody was
getting better. When you do this practice after many years, you
wonder if you’re helping anybody. And actually that was nice to see
those results, that’s why we sent in the abstract. You probably
wouldn’t have seen it if no one got better. But we did send that in
and we feel very confident that with the appropriately selected
ones, patients are getting better. And now we hope to maybe give
you an instrument to use so that you can select them too.
Dr Peter Gloviczki (Rochester, Minn). There is more and
more information in the literature that in venous thoracic outlet we
should do additional venous reconstruction in addition to decom-
pression of the thoracic outlet by resection of the first rib. And
that’s the practice that we are taking over at Mayo Clinic too.
And I’m wondering if you have any data, if the improvement
in the postoperative score is in any way related to patency of the
vein? Obviously we want to know if decompression alone is
enough as a first-stage operation or do we really have to do the
operations of Dr Molina, or what the St Louis group is proposing,
that we should do venous reconstruction at the same time.
Dr Freischlag. We actually have a paper that is in the process
of being published in Surgery that we presented at the Eastern
Vascular looking at our group of venous patients. And at Hopkinswe rarely get an acute thrombosed vein. We’ve only taken care of 3
or 4. We get our patients weeks to months to years later, which I’m
sure is your population too, with stenosis that we document by
duplex scan. And our treatment protocol has been to do the
first-rib resection scalenectomy and then do a venogram at 2
months and use balloon dilatation, which is required in about half
the patients.
We haven’t had to do venous bypasses or do patch angioplasty
because we do them transaxillary, which is different than some
other groups.
In this consortium, we are going to look at that to see whether
or not the supraclavicular approach with patch angioplasty that
some people are doing is superior. We’ve only lost a handful of
veins. We also treat chronically occluded ones too, which I
know you all know we have a series of about 15 that do open up
with anticoagulation postoperatively as well and we have a small
group of intermittent occlusion as well. But in the group that
was stenotic, I think we have one lost vein that just opened up
about 2 weeks ago on anticoagulation for 6 months. So yes,
they’re all open. And I think that also is probably the most
important thing that they won’t get better unless the vein is
open.
Dr Gloviczki. And just one follow-up question. You con-
cluded that in appropriately-selected patients this operation and
this technique works. Who are the appropriately-selected patients
in neurogenic Trans Atlantic Inter-Societal Consensus (TASC)?
Because I think nationwide, vascular surgeons operate less and less
neurogenic thoracic outlet syndrome. So could you tell us how do
you appropriately select the patients?
Dr Freischlag. Basically I think it’s an hour-long discussion
with patients that are highly motivated to get better. And we do
utilize the scalene block to help us determine which symptoms will
get better and what they will end up feeling like and what their
expectations are.
I actually think with neurogenic patients, you have to get the
expectations on the same page. So when you tell them what’s
going to get better, it has to do with the symptoms with their arm
and it’s not going to be their legs and their marriage and everything
else in their life. It’s just going to be that arm and that’s what’s
going to get better. And you’re going to have to work with me for
2 years to get there.
Lisa fields lots of telephone calls and lots of follow-up and
seeing them a lot over a period of time. They do like filling out the
study instrument.
The other thing is we have a great secretary named Nancy who
actually can screen them very well over the phone. And there are
many I never meet, because she tells me I don’t want to meet them.
And so I think similar to when a resident that you interview who
says something rude to your secretary, you never hire that resident
or fellow. It’s very similar. She can actually tell what’s going on
over the phone and knows whether we should see them or not, and
it helps Lisa and I out a lot.
So I think motivation, looking at what kind of pain manage-
ment they’re doing, what kind of opportunities they want to do in
the future. As you saw, about a third are disabled and you’re not
going to make them do something they weren’t doing, but you’ll
make them pain-free. We see them from all over. And having
partners all over the East Coast has been helpful, because in the
state of Pennsylvania this operation is not done by many people, so
we see all of them. And they’re far away from us, so we do need
help with that.
So I think it’s the gestalt. It’s 20 years of talking to them. It’s
Dr Machleder – who I really appreciate being here today. I sort of
brought him out of retirement to discuss this paper – teaching us
how to be able to look at these patients and having sympathy for
them. And not many people can do a big practice. We see probably
6 to 8 new patients a week now and operate on them every
Monday. So I think if you do have a big practice, you have many to
choose from.
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your patience with these patients that we find to be challenging.
My partner, Greg Landry, is doing functional outcome analy-
sis on patients with upper extremity procedures, including arterio-
venous access, to determine disability. And he has a very neatliving, such as putting a key in a lock and opening a doorknob and
dialing a phone, et cetera. Have you done any functional outcome
analysis or do you plan to do any for these patients?
Dr Freischlag. We have not, but it sounds like we need his
tool. Some of our questions do reflect functional outcome, but Ibattery of tests including activities performed for activities of daily think having a specific tool like that would be important.
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